TY - JOUR T1 - Orphanin FQ/Nociceptin-Mediated Desensitization of Opioid Receptor-Like 1 Receptor and μ Opioid Receptors Involves Protein Kinase C: A Molecular Mechanism for Heterologous Cross-Talk JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 502 LP - 509 DO - 10.1124/jpet.102.033159 VL - 302 IS - 2 AU - Chitra D. Mandyam AU - Deepak R. Thakker AU - Jennifer L. Christensen AU - Kelly M. Standifer Y1 - 2002/08/01 UR - http://jpet.aspetjournals.org/content/302/2/502.abstract N2 - Morphine tolerance in vivo is reduced following blockade of the orphanin FQ/nociceptin (OFQ/N)/opioid receptor-like 1 (ORL1) receptor system, suggesting that OFQ/N contributes to the development of morphine tolerance. We previously reported that a 60-min activation of ORL1 receptors natively expressed in BE(2)-C cells desensitized both μ and ORL1 receptor-mediated inhibition of cAMP. Investigating the mechanism(s) of OFQ/N-mediated μ and ORL1 receptor cross-talk, we found that pretreatment with the protein kinase C inhibitor, chelerythrine chloride (1 μM), blocked OFQ/N-mediated homologous desensitization of ORL1 and heterologous desensitization of μ opioid receptors. Furthermore, depletion of PKC by 12-O-tetradecanoylphorbol-13-acetate exposure (48 h, 1 μM) also prevented OFQ/N-mediated μ and ORL1 desensitization. OFQ/N pretreatment resulted in translocation of PKC-α, G protein-coupled receptor kinase 2 (GRK2) and GRK3 from the cytosol to the membrane, and this translocation was also blocked by chelerythrine. Reduction of GRK2 and GRK3 levels by antisense, but not sense DNA treatment blocks ORL1 and μ receptor desensitization. This suggests that PKC-α is required for GRK2 and GRK3 translocation to the membrane, where GRK can inactivate ORL1 and μ opioid receptors upon rechallenge with the appropriate agonist. Our results demonstrate for the first time the involvement of conventional PKC isozymes in OFQ/N-induced μ-ORL1 cross-talk, and represent a possible mechanism for OFQ/N-induced anti-opioid actions. The American Society for Pharmacology and Experimental Therapeutics ER -